Jefferies Group LLC reaffirmed their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research report released on Monday morning. The brokerage currently has a $160.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $175.00 target price (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the stock a buy rating in a research report on Thursday, July 27th. BMO Capital Markets reaffirmed an outperform rating and set a $160.00 target price (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. BidaskClub raised shares of Celgene Corporation from a sell rating to a hold rating in a research report on Wednesday, June 21st. Finally, Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the stock a buy rating in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twenty-one have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $150.49.

Celgene Corporation (NASDAQ:CELG) traded down 9.94% during midday trading on Monday, hitting $122.44. 17,677,507 shares of the stock traded hands. The firm has a market cap of $95.79 billion, a P/E ratio of 37.92 and a beta of 1.88. The company has a 50-day moving average price of $141.30 and a 200-day moving average price of $130.43. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the company earned $1.44 earnings per share. Celgene Corporation’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.33 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/10/20/celgene-corporation-celg-rating-reiterated-by-jefferies-group-llc.html.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,233 shares of company stock worth $6,268,259. Corporate insiders own 0.95% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Capital Counsel LLC NY lifted its position in Celgene Corporation by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its position in Celgene Corporation by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares during the period. Sowell Financial Services LLC lifted its position in Celgene Corporation by 0.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 13 shares during the period. South Texas Money Management Ltd. lifted its position in Celgene Corporation by 0.6% during the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 15 shares during the period. Finally, Flagship Harbor Advisors LLC lifted its position in Celgene Corporation by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 18 shares during the period. Institutional investors own 79.24% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.